Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 24:13:837457.
doi: 10.3389/fimmu.2022.837457. eCollection 2022.

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma

Massimiliano Gambella  1   2 , Simona Carlomagno  2 , Anna Maria Raiola  1 , Livia Giannoni  1 , Chiara Ghiggi  1 , Chiara Setti  2 , Chiara Giordano  2 , Silvia Luchetti  1 , Alberto Serio  1 , Alessandra Bo  1 , Michela Falco  3 , Mariella Della Chiesa  2 , Emanuele Angelucci  1 , Simona Sivori  2
Affiliations
Review

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma

Massimiliano Gambella et al. Front Immunol. .

Abstract

Surgical resection, chemotherapy and radiotherapy were, for many years, the only available cancer treatments. Recently, the use of immune checkpoint inhibitors and adoptive cell therapies has emerged as promising alternative. These cancer immunotherapies are aimed to support or harness the patient's immune system to recognize and destroy cancer cells. Preclinical and clinical studies, based on the use of T cells and more recently NK cells genetically modified with chimeric antigen receptors retargeting the adoptive cell therapy towards tumor cells, have already shown remarkable results. In this review, we outline the latest highlights and progress in immunotherapies for the treatment of Diffuse Large B-cell Lymphoma (DLBCL) patients, focusing on CD19-targeted immunotherapies. We also discuss current clinical trials and opportunities of using immunotherapies to treat DLBCL patients.

Keywords: CAR-NK cells; CAR-T cells; antibody-drug conjugates; bispecific T cell engagers; engineered T cells; genetic modification; monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Milestones achieved over the years regarding the evolution of immunotherapeutic strategies for the treatment of DLBCL patients. From allogenic bone marrow transplantation to the use of monoclonal antibodies, Bi-specific T-cell engagers (BiTEs) and T or NK cells engineered with chimeric antigen receptors (CARs). This figure has been created using BioRender.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. . The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood (2016) 127(20):2375–90. doi: 10.1182/blood-2016-01-643569 - DOI - PMC - PubMed
    1. Mohammed R, Milne A, Kayani K, Ojha U. How the Discovery of Rituximab Impacted the Treatment of B-Cell non-Hodgkin's Lymphomas. J Blood Med (2019) 10:71–84. doi: 10.2147/Jbm.S190784 - DOI - PMC - PubMed
    1. Smith MR. Rituximab (Monoclonal Anti-CD20 Antibody): Mechanisms of Action and Resistance. Oncogene (2003) 22(47):7359–68. doi: 10.1038/sj.onc.1206939 - DOI - PubMed
    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. . CHOP Chemotherapy Plus Rituximab Compared With CHOP Alone in Elderly Patients With Diffuse Large-B-Cell Lymphoma. N Engl J Med (2002) 346(4):235–42. doi: 10.1056/NEJMoa011795 - DOI - PubMed
    1. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. . CHOP-Like Chemotherapy Plus Rituximab Versus CHOP-Like Chemotherapy Alone in Young Patients With Good-Prognosis Diffuse Large-B-Cell Lymphoma: A Randomised Controlled Trial by the MabThera International Trial (MInT) Group. Lancet Oncol (2006) 7(5):379–91. doi: 10.1016/S1470-2045(06)70664-7 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources